The meta-analysis revealed (Figure 6) that ICIs vs. chemotherapy considerably enhanced the OS of NSCLC patients with EGFR wild-type (HR, 0.67; 95% CI, (0.60, 0.76)). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.